FDA Orange Book · active-ingredient family
Cyclophosphamide
Cyclophosphamide: 8 brands, 23 generics; first approved Feb 16, 1982; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 23 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
8
Generics (ANDA)
23
Listed patents
5
Next patent expiry
Jun 26, 2035
in 8 yr 10 mo
Brand (NDA) products
Originator applications
- CYCLOPHOSPHAMIDERLDRSSANDOZNDA 21715020233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/5ML (100MG/ML) SOLUTION INTRAVENOUS Rx - 1GM/10ML (100MG/ML) SOLUTION INTRAVENOUS Rx - 2GM/20ML (100MG/ML) SOLUTION INTRAVENOUS Rx - - CYCLOPHOSPHAMIDERLDRSBAXTER HLTHCARE CORPNDA 21765120232 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/2.5ML (200MG/ML) SOLUTION INTRAVENOUS Rx - 1GM/5ML (200MG/ML) SOLUTION INTRAVENOUS Rx - - AVYXA HOLDINGSNDA 21085220233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/ML (500MG/ML) SOLUTION INTRAVENOUS Rx - 1GM/2ML (500MG/ML) SOLUTION INTRAVENOUS Rx - 2GM/4ML (500MG/ML) SOLUTION INTRAVENOUS Rx - - CYCLOPHOSPHAMIDERLDRSEUGIA PHARMA SPECLTSNDA 21073520213 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/2.5ML (200MG/ML) SOLUTION INTRAVENOUS Rx - 1GM/5ML (200MG/ML) SOLUTION INTRAVENOUS Rx - 2GM/10ML (200MG/ML) SOLUTION INTRAVENOUS Rx - - CYCLOPHOSPHAMIDERLDRSDR REDDYSNDA 21250120203 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/2.5ML (200MG/ML) SOLUTION INTRAVENOUS Rx AP 1GM/5ML (200MG/ML) SOLUTION INTRAVENOUS Rx AP 2GM/10ML (200MG/ML) SOLUTION INTRAVENOUS Rx - - CYCLOPHOSPHAMIDERLDHIKMANDA 20385620132 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYTOXANRLDBAXTER HLTHCARENDA 012142-10 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG/VIAL INJECTABLE INJECTION Discontinued - 200MG/VIAL INJECTABLE INJECTION Discontinued - 500MG/VIAL INJECTABLE INJECTION Discontinued - 1GM/VIAL INJECTABLE INJECTION Discontinued - 2GM/VIAL INJECTABLE INJECTION Discontinued - 100MG/VIAL INJECTABLE INJECTION Discontinued - 200MG/VIAL INJECTABLE INJECTION Discontinued - 500MG/VIAL INJECTABLE INJECTION Discontinued - 2GM/VIAL INJECTABLE INJECTION Discontinued - 1GM/VIAL INJECTABLE INJECTION Discontinued - - CYTOXANRLDBAXTER HLTHCARENDA 012141-2 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 50MG TABLET ORAL Rx - 25MG TABLET ORAL Rx -
Generic (ANDA) products (23)
Abbreviated applications
- CYCLOPHOSPHAMIDEHAINAN POLYANDA 21863220243 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDEEPIC PHARMA LLCANDA 21864420243 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDEEIRGENANDA 21828220242 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYCLOPHOSPHAMIDENEXUSANDA 21678320242 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/2.5ML (200MG/ML) SOLUTION INTRAVENOUS Rx AP 1GM/5ML (200MG/ML) SOLUTION INTRAVENOUS Rx AP - CYCLOPHOSPHAMIDEHIKMAANDA 21695820233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDEZYDUS LIFESCIENCESANDA 21155220232 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYCLOPHOSPHAMIDESUNNYANDA 21508920233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDESAGENT PHARMS INCANDA 21452920233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDEALEMBICANDA 21589220222 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYCLOPHOSPHAMIDEXGEN PHARMSANDA 21175720223 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDECIPLAANDA 21160820192 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYCLOPHOSPHAMIDEAMNEALANDA 21004620183 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDESENORES PHARMSANDA 20987220182 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Rx AB 50MG CAPSULE ORAL Rx AB - CYCLOPHOSPHAMIDEANI PHARMSANDA 20701420182 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG CAPSULE ORAL Discontinued - 50MG CAPSULE ORAL Discontinued - - CYCLOPHOSPHAMIDEHENGRUI PHARMAANDA 20455520143 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDERSBAXTER HLTHCAREANDA 04074520083 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Rx AP 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - CYCLOPHOSPHAMIDEROXANEANDA 04003219992 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 25MG TABLET ORAL Discontinued - 50MG TABLET ORAL Discontinued - - TEVA PARENTERALANDA 04001519935 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG/VIAL INJECTABLE INJECTION Discontinued - 200MG/VIAL INJECTABLE INJECTION Discontinued - 500MG/VIAL INJECTABLE INJECTION Discontinued - 1GM/VIAL INJECTABLE INJECTION Discontinued - 2GM/VIAL INJECTABLE INJECTION Discontinued - - CYCLOPHOSPHAMIDEBAXTER HLTHCAREANDA 0883741986
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued - - CYCLOPHOSPHAMIDEBAXTER HLTHCAREANDA 0883711986
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG/VIAL INJECTABLE INJECTION Discontinued - - CYCLOPHOSPHAMIDEBAXTER HLTHCAREANDA 0883721986
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG/VIAL INJECTABLE INJECTION Discontinued - - CYCLOPHOSPHAMIDEBAXTER HLTHCAREANDA 0883731986
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued - - BEDFORDANDA 08744219835 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG/VIAL INJECTABLE INJECTION Discontinued - 200MG/VIAL INJECTABLE INJECTION Discontinued - 500MG/VIAL INJECTABLE INJECTION Discontinued - 1GM/VIAL INJECTABLE INJECTION Discontinued - 2GM/VIAL INJECTABLE INJECTION Discontinued -
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 9662342 | in 8 yr 10 mo | Product | |
| 10849916 | in 8 yr 10 mo | Product | |
| 11382923 | in 9 yr 3 mo | Product | |
| 10993952 | in 9 yr 5 mo | Product | |
| 12329767 | in 9 yr 5 mo | Product |
Approval history
FDA approval span
First approval
45 yr 4 mo ago
Most recent approval
1 yr 10 mo ago
Approvals span 1982–2024 across 31 FDA applications.
Brand (NDA) 826%
Generic (ANDA) 2374%
Cyclophosphamide: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Cyclophosphamide
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo